SEC Reporting: Learn Why Samuel Isaly’s Orbimed Advisors Llc Just Purchased Roka Bioscience, Inc Stake?

SEC Reporting: Learn Why Samuel Isaly's Orbimed Advisors Llc Just Purchased Roka Bioscience, Inc Stake?

The New Samuel Isaly’s Orbimed Advisors Llc Holding in Roka Bioscience, Inc

Orbimed Advisors Llc filed with the SEC SC 13D/A form for Roka Bioscience, Inc. The form can be accessed here: 000094787116001662. As reported in Samuel Isaly’s Orbimed Advisors Llc’s form, the filler as of late owns 49.1% or 1,464,671 shares of the -company.

Roka Bioscience, Inc stake is a new one for the for the hedge fund and it was filed because of activity on November 10, 2016. We feel this shows Samuel Isaly’s Orbimed Advisors Llc’s positive view for the stock. For a hedge fund managing $6.70 billion in assets and having 72+ active experts, we at Financialmagazine have no doubt the buy is a bullish signal.

The hedge fund is active investor in the Finance sector. In the manager’s last 13-F, we saw 25% of Samuel Isaly’s Orbimed Advisors Llc’s US equities portfolio is in this sector.

Reasons Why Samuel Isaly’s Orbimed Advisors Llc Bought – Roka Bioscience, Inc Stock

Item 4. Purpose of Transaction

Not applicable. As described more fully in Item 1 above, the event giving rise to the obligation of the Reporting Persons to file this Amendment No. 2 did not involve any transactions effected by one or more Reporting Persons with respect to the Shares.

The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer’s business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Common Stock in particular, as well as other developments and other investment opportunities.Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time.If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of the Common Stock or otherwise, they may acquire shares of Common Stock or other securities of the Issuer either in the open market or in privately negotiated transactions.Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions.

Except as set forth in this Amendment No. 2, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries, (c) a sale or transfer of a material amount of the assets of the Issuer or any of its subsidiaries, (d) any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) any material change in the Issuer’s capitalization or dividend policy of the Issuer, (f) any other material change in the Issuer’s business or corporate structure, (g) any change in the Issuer’s charter or bylaws or other instrument corresponding thereto or other action which may impede the acquisition of control of the Issuer by any person, (h) causing a class of the Issuer’s securities to be deregistered or delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association, (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act or (j) any action similar to any of those enumerated above.

Roka Bioscience, Inc Institutional Sentiment

Latest Security and Exchange filings show 26 investors own Roka Bioscience, Inc. The institutional ownership in Q3 2015 is low, at 696.79% of the outstanding shares. This is decreased by 584945 the total institutional shares. 12820851 were the shares owned by these institutional investors. In total 1 funds opened new Roka Bioscience, Inc stakes, 4 increased stakes. There were 9 that closed positions and 7 reduced them.

Tpg Group Holdings Sbs Advisors Inc is an institutional investor bullish on Roka Bioscience, Inc, owning 2989282 shares as of Q3 2015 for 0.03% of its portfolio. Birchview Capital Lp owns 152307 shares or 0.21% of its portfolio. NY Aisling Capital Llc have 0.28% of their stock portfolio for 811886 shares. Further, Nea Management Company Llc reported stake worth 0.41% of its US stock portfolio. The NY Drill Craig A owns 1600000 shares. Roka Bioscience, Inc is 4.44% of the manager’s US portfolio.

Business Profile

Roka Bioscience, Inc. is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture-based assays, immunochemical-based assays and molecular-based assays. The Company sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing and a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

Samuel Isaly’s Orbimed Advisors Llc website.

Insitutional Activity: The institutional sentiment increased to 0.5 in 2016 Q2. Its up 0.23, from 0.27 in 2016Q1. The ratio increased, as 4 funds sold all Roka Bioscience Inc shares owned while 2 reduced positions. 1 funds bought stakes while 2 increased positions. They now own 11.75 million shares or 4.44% less from 12.30 million shares in 2016Q1.

Bridgeway Cap Management reported 207,500 shares or 0% of all its holdings. Renaissance Ltd Liability Com accumulated 55,400 shares or 0% of the stock. Cannell Peter B And accumulated 58,098 shares or 0% of the stock. Weiss Multi holds 0% of its portfolio in Roka Bioscience Inc (NASDAQ:ROKA) for 54,675 shares. Blackrock last reported 120 shares in the company. Wells Fargo Mn reported 100 shares or 0% of all its holdings. Tpg Grp Hldgs (Sbs) Advsrs has 2.99M shares for 0.02% of their US portfolio. Vanguard Gp Inc reported 22,486 shares or 0% of all its holdings. Royal Retail Bank Of Canada last reported 0% of its portfolio in the stock. Orbimed reported 3.22 million shares or 0.02% of all its holdings. Manufacturers Life Insurance Com The holds 0% of its portfolio in Roka Bioscience Inc (NASDAQ:ROKA) for 746 shares. Geode Management Ltd Liability holds 0% of its portfolio in Roka Bioscience Inc (NASDAQ:ROKA) for 20,739 shares. The New York-based Goldman Sachs Grp has invested 0% in Roka Bioscience Inc (NASDAQ:ROKA). Savings Bank Of America Corp De has invested 0% of its portfolio in Roka Bioscience Inc (NASDAQ:ROKA). Birchview Cap Ltd Partnership holds 0.1% of its portfolio in Roka Bioscience Inc (NASDAQ:ROKA) for 252,307 shares.

About 150,592 shares traded hands or 247.06% up from the average. Roka Bioscience Inc (NASDAQ:ROKA) has declined 25.00% since April 12, 2016 and is downtrending. It has underperformed by 29.98% the S&P500.

Roka Bioscience, Inc. is a molecular diagnostics company. The company has a market cap of $8.22 million. The Firm is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. It currently has negative earnings. The Firm offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications.

Roka Bioscience Inc (NASDAQ:ROKA) Ratings Coverage

Out of 3 analysts covering Roka Bioscience (NASDAQ:ROKA), 0 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 0 are positive. $4 is the highest target while $1 is the lowest. The $1.50 average target is -64.29% below today’s ($4.2) stock price. Roka Bioscience has been the topic of 7 analyst reports since August 14, 2015 according to StockzIntelligence Inc. Leerink Swann downgraded the shares of ROKA in a report on Monday, March 7 to “Market Perform” rating. The firm has “Hold” rating by Zacks given on Tuesday, August 25. The stock of Roka Bioscience Inc (NASDAQ:ROKA) has “Hold” rating given on Tuesday, September 8 by Zacks. Leerink Swann maintained Roka Bioscience Inc (NASDAQ:ROKA) rating on Friday, August 14. Leerink Swann has “Outperform” rating and $4 price target.

More notable recent Roka Bioscience Inc (NASDAQ:ROKA) news were published by: Marketwatch.com which released: “Roka Bioscience upgraded to outperform from market perform at Leerink Partners” on July 17, 2014, also Prnewswire.com with their article: “Roka Bioscience, Inc. Announces One-For-Ten Reverse Stock Split” published on October 11, 2016, Prnewswire.com published: “Roka Bioscience, Inc. Prices Private Placement of Preferred Stock and Warrants” on September 16, 2016. More interesting news about Roka Bioscience Inc (NASDAQ:ROKA) were released by: Prnewswire.com and their article: “Roka Bioscience to Report Third Quarter 2016 Financial Results On November 7, 2016” published on October 31, 2016 as well as Prnewswire.com‘s news article titled: “Roka Bioscience to Present at the Sidoti & Company Fall 2016 Emerging Growth …” with publication date: October 25, 2016.

According to Zacks Investment Research, “Roka Bioscience, Inc. is a molecular diagnostics company. It is focused on developing and commercializing advanced testing solutions for the food safety testing market. Roka provides Atlas instrument, a fully automated molecular diagnostic testing instrument to reduce labor costs and operator error in high-volume foodborne pathogen testing laboratories. The company also offers atlas detection assays that include tests for Salmonella, Listeria, E. coli O157:H7, Shiga toxin-producing E. coli, and Listeria monocytogenes, as well as related consumable supplies. Roka Bioscience, Inc. is headquartered in Warren, New Jersey.”

ROKA Company Profile

Roka Bioscience, Inc., incorporated on September 3, 2009, is a molecular diagnostics company. The Firm is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Firm offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture assays, immunochemical assays and molecular assays. The Firm sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing instrument designed to reduce labor costs and operator error in foodborne pathogen testing laboratories. The Atlas instrument is a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment